Exelon Patch rivastigmine regulatory update

FDA approved an sNDA to expand the label of Exelon Patch rivastigmine transdermal patch to include the 13.3 mg/24 hour dose to treat mild to moderate dementia associated with Parkinson's disease (PD) ...